Trial Profile
A study evaluating cost effectiveness and efficacy of Plerixafor to improve mobilization in multiple myeloma patients who behave as poor-mobilizers.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jul 2017
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 19 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association